Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 14/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5936865 | 0.83 | EGLN2 (0.45) | EGLN2EGLN1CHEK1PTPN1PTPRA | |
| SCHEMBL967020 | 0.80 | EGLN1 (0.65) | EGLN2EGLN1 | |
| SCHEMBL1973999 | 0.78 | MAPT (0.42) | EGLN2EGLN1 | |
| SCHEMBL4724129 | 0.78 | EGLN2 (0.69) | EGLN2EGLN1 | |
| SCHEMBL5488026 | 0.74 | CHEK1 (0.42) | CHEK1PTPN1PTPRAMAP3K8ICAM1 | |
| SCHEMBL966034 | 0.70 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL2350847 | 0.68 | EGLN1 (0.63) | EGLN2EGLN1 | |
| SCHEMBL14941692 | 0.68 | EGLN1 (0.50) | EGLN2EGLN1 | |
| SCHEMBL966776 | 0.68 | EGLN1 (0.51) | EGLN2EGLN1 | |
| SCHEMBL1527650 | 0.67 | EGLN2 (0.48) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | EGLN2 11/4885EGLN1 25/4885CHEK1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.